Platelet and vascular thromboxane A2/prostaglandin H2 receptors. Evidence for different subclasses in the rat
- PMID: 1830482
- DOI: 10.1016/0006-2952(91)90316-w
Platelet and vascular thromboxane A2/prostaglandin H2 receptors. Evidence for different subclasses in the rat
Abstract
Thromboxane A2 (TXA2) and its precursor prostaglandin H2 (PGH2) induce platelet aggregation and vascular contraction through shared cell surface receptors commonly referred to as TXA2 or TXA2/PGH2 receptors. Whether different subclasses of TXA2/PGH2 receptors exist in platelets and vascular smooth muscle cells is controversial. In this study, TXA2 receptors on washed rat and human platelets and cultured rat aortic smooth muscle cells (RASMC) were characterized using radioligand competition binding assays with the 125I-labeled TXA2/PGH2 receptor agonist [1S-(1 alpha,2 beta(5Z),3 alpha(1E,3R*),4 alpha)] -7- [3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl) -7- oxabicyclo-[2.2.1]- heptan-2-yl] -5- heptenoic acid (I-BOP) and various agonists and antagonists. Scatchard analyses of equilibrium binding data revealed Kd values of 205 +/- 68 pM (N = 6), 2.2 +/- 0.3 nM (N = 9) and 310 +/- 60 pM (N = 7) and Bmax values of 1.3 +/- 0.45 fmol/10(6) platelets, 2.8 +/- 0.2 fmol/10(6) platelets and 20.9 +/- 2.2 fmol/10(6) cells for rat and human platelets and RASMC, respectively. Concentration-dependent increases in intracellular free Ca2+ concentrations induced by I-BOP were observed in RASMC loaded with the calcium sensitive dye fura-2. The IC50 values for various TXA2/PGH2 analogues in competition binding assays with 125I-BOP were determined. Based on their IC50 values, the rank orders were I-BOP less than L657925 less than ONO11113 less than or equal to SQ29548 less than PTA-TPO less than PTA-NO less than or equal to L657926 less than or equal to I-PTA-OH less than PTA-OH[2] = meta-I-PTA-PO less than or equal to ONO11120[2] = ONO11120[1] less than PTA-OH[1] in rat platelets. I-BOP less than SQ29548 less than PTA-TPO = L657925 less than or equal to ONO11113 less than I-PTA-OH less than PTA-NO less than or equal to meta-I-PTA-PO less than or equal to PTA-OH[2] less than ONO11120[2] less than or equal to ONO11120[1] less than L657926 less than or equal to PTA-OH[1] in human platelets, and I-BOP less than L657925 less than ONO11113 less than or equal to SQ29548 less than ONO11120[2] less than or equal to L657926 less than or equal to PTA-OH[2] less than PTA-TPO less than ONO11120[1] less than I-PTA-OH less than meta-I-PTA-PO less than PTA-NO less than PTA-OH[1] in RASMC.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Differential effect of pH on thromboxane A2/prostaglandin H2 receptor agonist and antagonist binding in human platelets.J Biol Chem. 1991 Jul 25;266(21):13752-8. J Biol Chem. 1991. PMID: 1830308
-
7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.J Pharmacol Exp Ther. 1992 Aug;262(2):632-7. J Pharmacol Exp Ther. 1992. PMID: 1386885
-
Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes. A radioligand binding study of human platelets.J Clin Invest. 1989 Dec;84(6):1883-91. doi: 10.1172/JCI114375. J Clin Invest. 1989. PMID: 2531760 Free PMC article.
-
Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors.Fed Proc. 1987 Jan;46(1):149-53. Fed Proc. 1987. PMID: 2948839 Review.
-
Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.Cardiovasc Drug Rev. 2001 Summer;19(2):97-115. doi: 10.1111/j.1527-3466.2001.tb00058.x. Cardiovasc Drug Rev. 2001. PMID: 11484065 Review.
Cited by
-
Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha.Br J Pharmacol. 1996 Mar;117(6):1171-80. doi: 10.1111/j.1476-5381.1996.tb16712.x. Br J Pharmacol. 1996. PMID: 8882612 Free PMC article.
-
Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini.Br J Pharmacol. 1994 Jun;112(2):377-85. doi: 10.1111/j.1476-5381.1994.tb13082.x. Br J Pharmacol. 1994. PMID: 8075855 Free PMC article.
-
Characterization of the thromboxane (TP-) receptor subtype involved in proliferation in cultured vascular smooth muscle cells of rat.Br J Pharmacol. 1995 Sep;116(2):1801-8. doi: 10.1111/j.1476-5381.1995.tb16666.x. Br J Pharmacol. 1995. PMID: 8528563 Free PMC article.
-
Fatty acid modulation of tumor cell-platelet-vessel wall interaction.Cancer Metastasis Rev. 1992 Nov;11(3-4):389-409. doi: 10.1007/BF01307189. Cancer Metastasis Rev. 1992. PMID: 1423824 Review.
-
Prostanoid receptor antagonists: development strategies and therapeutic applications.Br J Pharmacol. 2009 Sep;158(1):104-45. doi: 10.1111/j.1476-5381.2009.00317.x. Epub 2009 Jul 15. Br J Pharmacol. 2009. PMID: 19624532 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous